A drug from Marathon Pharmaceuticals has ignited a firestorm on Capitol Hill and beyond. What makes it different than the $750,000 drug that came before it?
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
Donald Trump’s pick to run HHS has been under fire for trading health care stocks but at least six senators at his confirmation hearings also own such stocks.
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
Una investigación de Kaiser Health News analiza las acciones de compañias farmacéuticas para manipular los precios de medicamentos huérfanos, utilizados para tratar enfermedades raras.
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren’t new or were repurposed multiple times, an investigation shows.
El 21st Century Cures Act que firmó el presidente Barack Obama el martes 13 de diciembre es un éxito legislativo para la industria farmacéutica. Qué podría pasar con los servicios de medicina preventiva.
A breakdown of winners — and a few losers — in the sprawling Cures Act approved by the House.
Three lobbyists for every member of Congress in a push to pass a bill that increases research funding and speeds up approvals.
The FDA’s drug-approval team is short more than 700 people and losing skilled staff members to the drug industry.
In a report out Tuesday, hospital groups said drug prices have skyrocketed since 2013, triggering a huge increase in what hospitals spend on pharmaceuticals.
Researchers examine the Food and Drug Administration’s “revolving door” regarding employees who worked on cancer and hematology drugs.
Four years after a huge push to speed generics to market, the FDA has more than 4,000 generics waiting for approval.
Researchers at Harvard University examined thousands of studies to determine why drug prices have climbed and what might be done about it.
Some experts said the findings stemming from this systematic review of existing studies was reassuring, but not surprising.